Clinical Data ECO 2026: tirzepatide shows potential for T1D treatment Pharmaceutical TechnologyDuring ECO 2026, a study was presented analysing the use of tirzepatide, a dual GIP and GLP-1 agonist, in treating type 1 diabetes (T1D).Metabolic & GLP-1Read full story pharminent May 15, 2026 Pharmaceutical Technology During ECO 2026, a study was presented analysing the use of tirzepatide, a dual GIP and GLP-1 agonist, in treating type 1 diabetes (T1D). Metabolic & GLP-1 Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Biogen’s Alzheimer’s results bolster tau theory–and Denali’s next gen candidateNext: Biopharma industry endorses Pazdur for FDA commissioner role Related Stories Clinical Data Parsortix study shows promise for ADC target detection pharminent August 3, 2026 Clinical Data Novo setback casts doubt on a new way to treat heart disease pharminent July 31, 2026 Clinical Data Altimmune rises as GLP-1/GIP drug curbs heavy drinking in mid-stage study pharminent July 28, 2026
